The efficacy and safety between efgartigimod and intravenous immunoglobulin in elderly generalized myasthenia gravis patients

Copyright © 2025 The Author(s). Published by Elsevier Inc. All rights reserved.

Détails bibliographiques
Publié dans:Clinical immunology (Orlando, Fla.). - 1999. - 274(2025) vom: 17. Mai, Seite 110457
Auteur principal: Zhang, Chaoyue (Auteur)
Autres auteurs: Li, Xiang, Deng, Yufei, Luo, Haocheng, Wang, Shuangshuang, Yan, Xianni, Yang, Xiaojun, Jiang, Qilong
Format: Article en ligne
Langue:English
Publié: 2025
Accès à la collection:Clinical immunology (Orlando, Fla.)
Sujets:Comparative Study Journal Article Randomized Controlled Trial AChR-Ab(+) Efficacy Efgartigimod Elderly IVIg Myasthenia gravis Immunoglobulins, Intravenous plus... Pyridostigmine Bromide KVI301NA53 Receptors, Cholinergic efgartigimod alfa 961YV2O515 Antibodies, Monoclonal, Humanized